• The Korean journal of internal medicine
• /
• v.33 no.6
• /
• pp.1143-1149
• /
• 2018

Background/Aims: The purpose of this study was to compare maternal and neonatal outcomes in Korean women with type 2 diabetes and nondiabetic controls. Methods: We performed a retrospective survey of 200 pregnancies in women with type 2 diabetes (n = 100) and nondiabetic controls (n = 100) who delivered from 2003 to 2010 at Cheil General Hospital & Women's Healthcare Center, Korea. We compared maternal characteristics as well as maternal and neonatal outcomes between groups matched by age, pre-pregnancy weight, body mass index, parity, and gestational age at delivery. Results: The number of infants that were small for gestational age and the rate of major congenital malformations were not significantly different. However, women with type 2 diabetes showed a slightly higher risk for primary caesarean section (35.0% vs. 18.0%, p = 0.006) as well as pre-eclampsia (10.0% vs. 2.0%, p = 0.017), infections during pregnancy (26.0% vs. 2.0%, p < 0.001), neonatal weight ($3,370{\pm}552.0$ vs. $3,196{\pm}543.3$, p = 0.025), large for gestational age (22.0% vs. 9.0%, p = 0.011), and macrosomia (15.0% vs. 5.0%, p = 0.018) compared to nondiabetic controls. Conclusions: Maternal and neonatal outcomes for women with type 2 diabetes were worse than those for nondiabetic controls. Diabetic women have a higher risk for primary caesarean section, pre-eclampsia, infections during pregnancy, large neonatal birth weight, large for gestational age, and macrosomia.

• 대한예방의학회:학술대회논문집
• /
• 2001.10a
• /
• pp.199-200
• /
• 2001

• Biomolecules & Therapeutics
• /
• v.3 no.1
• /
• pp.47-53
• /
• 1995

DA-125, a new anthracycline antitumor antibiotic, was administered at dose levels of 0, 0.2, 0.6 and 1.8 mg/kg/day intravenously to pregnant New Zealand White rabbits from day 6 through 18 of gestation. The does were subjected to the caesarean section on day 28 of gestation. Effects of test agent on general toxicity of does and embryonic development of F1 fetuses were examined. At 1.8 mg/kg, the organ weight for ovary of does was significantly decreased. The decrease in the number of corpus lutea, implantations and litter size, and the increase in the rate of resorptions were also observed. In addition, various types of external, visceral and skeletal malformations occurred in fetuses at an incidence of 7.7, 7.7 and 20.6%, respectively. The results show that the no effect dose levels (NOELs) of DA-125 are 0.6 mg/kg/day for does and F1 fetuses.

• Korean Journal of Veterinary Research
• /
• v.34 no.3
• /
• pp.601-607
• /
• 1994

This study was carried out to investigate the potential of phenol to induce embryotoxicity in the Sprague-Dawley rat. Seventy mated rats were distributed among three treated troups, a vehicle control group and a negative control group. Phenol was at dose levels of 20, 60 and 180mg/kg/day adminsistered by gavage to pregnant rats three times per day from days 7 to 12 of gestation. All dams were subjected to the caesarean section on day 20 of gestation. At 120mg/kg, dams exhibited decreased locomotivity. In addition, both weight reduction and retarded ossification of fetuses were observed. There were no signs of maternal toxicity or embryotoxicity at 20 and 60mg/kg. The results show that phenol induces fetal growth retardation at maternally subtoxic dose in rats.

• Toxicological Research
• /
• v.17 no.2
• /
• pp.83-90
• /
• 2001

The background control data were compiled from rat developmental toxicity studies con-ducted at Toxicology Research Center, KRICT during the 1993-1999 period. These data were assembled in order to provide background in formation for the maternal and fetal data collected in 13 developmental toxicity studies using Sprague-Dawley rats. A total of 325 mated females were used in these studies during the seven-year period and overall pregnancy rate of these females was 93.8%. The present background control data included body weights, food consumption, hematological values, and organ weights of pregnant females, caesarean section data, and fetal examination data. These data can be used not only as a historical database for the meaningful interpretation of data from reproductive and developmental toxicity studies, but also as a contribution to biological characterization oj Sprague-Dawley rats.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.30 no.4
• /
• pp.203-212
• /
• 2017

Objectives: To report the efficacy of traditional Korean medicine to an infertile patient who repeatedly failed in vitro fertilization. Methods: The patient was diagnosed with adenomyosis and failed in vitro fertilization 9 times. Her dysmenorrhea and physical symptoms were improved through traditional Korean medicine and she was pregnant with the 10th attempt of in vitro fertilization. She had bleeding during pregnancy due to adenomyosis and took herbal medicines to maintain stable condition. Results: During the treatment period, the uterine thickness due to adenomyosis was reduced and her dysmenorrhea was improved. She was pregnant by in vitro fertilization and gave birth to a healthy child by Caesarean section. Conclusions: This case report shows that traditional Korean medical treatments work to improve the success rate of in vitro fertilization.

• Toxicological Research
• /
• v.9 no.1
• /
• pp.61-67
• /
• 1993

LBD-005, a newly developed recombinant granulocyte-macrophage colony-stimulating factor, was at dose levels of 0, 20, 80 and 320ng/kg/day administered subcutaneously to pregnat New Zealand White rabbits during the organogenetic period. The dams were subjected to caesarean section on day 28 of pregnancy. Effects of test substance on dams and embryonal development of fetuses were examined. No treatment-related changes in clinical signs and necropsy findings of dams were observed in all groups. At 80 and 320 ng/kg, a significant decrease in food consumption followed by a loss in body weight was found.

• Toxicological Research
• /
• v.9 no.1
• /
• pp.99-105
• /
• 1993

LBD-007, a newly developed recombinant human interferon alphaA, was at dose levels of 0.3 $\times$$10^6$ , 6 $\times$ $10^6$ and 12 $\times$ $10^6$ IU/kg/day administered subcutaneously to pregnant New Zealand White rabbits during the organogenetic period. Cyclophosphamide was used as a positive control. All pregnant females were subjected to the caesarean section on day 28 of pregnancy. Effect of test substance on dams and embryonal development of fetuses were examined. 1. No treatment-related changes in clinical signs, food consuption, body weight and necropsy findings of dams were observed.

• Toxicological Research
• /
• v.9 no.1
• /
• pp.83-98
• /
• 1993

LBD-007, a newly developed recombinant human interferon alpha A, was at dose levels of 0, 3 $\times$ $10^6$, 6 $\times$ $10^6$ and 12 $\times$ $10^6$ IU/kg/day administered subctaneously to pregnant Sprague-Dawley rats during the organogenetic period. Ethylenethiourea was used as a positive control. 2/3 of dams per group were subjected to caesarean section on day 20 of pregnancy and the remaining 10 dams per group were allowed to deliver. Effects of test substance on dams, embryonal development development of F1 fetuses, as well as growth, behaviour and mating performance of F1 offspring were examined. 1. No treatment-related changes in clinical signs, food consumption, body weight and necropsy findings of dams were observed.

• Biomolecules & Therapeutics
• /
• v.6 no.2
• /
• pp.151-158
• /
• 1998

Aspalatone, a new antithrombotic agent, was administered orally to pregnant Sprague-Dawley rats during the organogenetic period at dose levels of 0, 20, 100 and 500 mg/kg/day. All dams were subjected to caesarean section on day 20 of pregnancy. Effects of test substance on dams and embryonic development of F1 fetuses were examined There were treatment-related decreases in body weight and food consumption in the 500 mg/kg group. There was a increase in the spleen weight in the 100 and 500 mg/kg groups. Develo-pmental toxicity was evident as decreased fetal body weights and increased fetal malformations in the 500 mg/ kg group. External and skeletal malformations of fetuses occurred at an incidence of 1 and 8.2%, respectively. In addition, there was a delay in ossification of sternebrae and sacrocaudal vertebrae in the 500 mg/kg group. The results show that the no observed adverse effect dose level (NOAEL) for maternal toxicity was 20 mg/kg/ day and for developmental toxicity was 100 mg/kg/day.